3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
74
Pancreatic Neoplasms
54
Carcinoma, Non-Small-Cell Lung
29
Triple Negative Breast Neoplasms
27
Neoplasm Metastasis
16
Squamous Cell Carcinoma of Head and Neck
15
Ovarian Neoplasms
12
Neoplasms
12
Lung Neoplasms
11
Esophageal Squamous Cell Carcinoma
11
Stomach Neoplasms
10
Esophageal Neoplasms
10
Head and Neck Neoplasms
9
Uterine Cervical Neoplasms
7
Melanoma
7
Cholangiocarcinoma
7
Small Cell Lung Carcinoma
6
Recurrence
6
Sarcoma
5
Pancreatic Adenocarcinoma
5
Inflammatory Breast Neoplasms
5
Fallopian Tube Neoplasms
5
Urinary Bladder Neoplasms
4
Colorectal Neoplasms
4
Advanced Pancreatic Cancer
4
Carcinoma, Transitional Cell
3
Carcinoma, Ovarian Epithelial
3
Breast Neoplasms, Male
3
Adenocarcinoma
3
Uveal Melanoma
2
Interventions
seribantumab
2
Istiratumab
1
Gemcitabine
1
Docetaxel
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Fibromatosis, Gingival, 2
×
Albumin-Bound Paclitaxel
×
Clear all
NCT02399137
2018-09-18
CARRIE
Merrimack Pharmaceuticals
Phase 2
Completed
88 enrolled